Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present CRISPR Therapeutics AG (NASDAQ: CRSP).

Full DD Report for CRSP

You must become a subscriber to view this report.


Recent News from (NASDAQ: CRSP)

CRISPR Therapeutics: Clinical Debut Sets Up Round 1 Of Editing Battle Royale
This article is part of a series on genomic medicine which is poised to transform healthcare over the next two decades. The first article entitled Genomic Medicine: Catch the Gene Therapy Wave is a primer providing context for company-specific articles in process. CRISPR Therapeutics (...
Source: SeekingAlpha
Date: May, 17 2018 16:05
Bluebird Bio: Gene Therapy Best In Class
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two...
Source: SeekingAlpha
Date: May, 16 2018 11:31
Rounds Report: Omeros Rallied Robustly While Stellar FDA Due Diligence To Help Orphan Disease Innovators
Those who keep learning will keep rising in life. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for May 14, 2018. As usual, we’ll elucidate notable trading analytics for the day, recent insider transactions, and interesting market d...
Source: SeekingAlpha
Date: May, 16 2018 06:38
Biotechs Emerge Unscathed And Ready To Go!
Biotech Pulse Biotechs have a pulse now, and it's beginning to beat a little harder! As President Trump on Friday, May 11, delivered a blueprint, American Patients First , to lower drug prices the early indications appear to be that the biotech and pharmaceutical industries have jumped th...
Source: SeekingAlpha
Date: May, 15 2018 08:28
CRISPR Therapeutics Announces Presentations at the ASGCT 21st Annual Meeting
ZUG, Switzerland and CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of the CRISPR team will make a series of presenta...
Source: GlobeNewswire
Date: May, 15 2018 08:00
Genomic Medicine: Catch The Gene Therapy Wave
Genomic medicine is the future of healthcare. Spawned by the Human Genome Project “HGP” this precise and personal approach to medicine is an emerging discipline with enormous disruptive potential. Though nascent, Genomic medicine is showing signs of being the transformative for...
Source: SeekingAlpha
Date: May, 14 2018 15:12
CRISPR Therapeutics Q1 2018 Review
Introduction Most Hollywood Fiction is (loosely) based on actual events or concepts, and then the writers let their imaginations run wild. For example, the film San Andreas starring Dwayne "The Rock" Johnson is a disaster flick that revolves around the San Andreas fault triggering a massiv...
Source: SeekingAlpha
Date: May, 11 2018 20:03
Keeping It Simple On The Short Side
Welcome to Editor's Notes! I aim to sort through the ideas we publish each day and highlight a few that may be of interest to readers, along with comments that may add a helpful gloss. If you have thoughts, comment below or send me a direct message and let me know what you think. Your fe...
Source: SeekingAlpha
Date: May, 11 2018 13:20
Next-generation CRISPR gene editing technology on the way
ScienceDaily reports that researchers at the Joint Institute of Metrology and Biology, a collaboration between Stanford University and the National Institute of Standards and Technology,  have developed a new CRISPR platform called MAGESTIC ("multiplexed accurate genome editing with s...
Source: SeekingAlpha
Date: May, 11 2018 09:44
Pushing Preclinical: Wave Of Early-Stage Biotech IPOs Tests Investor Risk Appetite
Biotechs are among the most risky of IPOs due to the binary nature of the success… or failure of their drugs. In the past, most biotechs delayed public offerings until they at least showed clinical evidence of their safety or efficacy. But in 2018, biotechs are increasingly going publ...
Source: SeekingAlpha
Date: May, 09 2018 05:37

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1857.6965.4065.9957.203,806,786
2018-05-1757.6965.4065.9957.203,806,786

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-24600,2911,188,52750.5071Short
2018-05-23459,347886,96251.7888Short
2018-05-22241,530447,82153.9345Short
2018-05-21434,706657,29766.1354Short
2018-05-18776,0391,355,06857.2694Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CRSP.


About CRISPR Therapeutics AG (NASDAQ: CRSP)

Logo for CRISPR Therapeutics AG (NASDAQ: CRSP)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $2,477,044,480 - 05/11/2018
  • Issue and Outstanding: 46,976,000 - 02/28/2018

 


Recent Filings from (NASDAQ: CRSP)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 18 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 18 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 02 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 08 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: February, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 12 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: February, 08 2018

 

 


Daily Technical Chart for (NASDAQ: CRSP)

Daily Technical Chart for (NASDAQ: CRSP)


Stay tuned for daily updates and more on (NASDAQ: CRSP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CRSP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CRSP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of CRSP and does not buy, sell, or trade any shares of CRSP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/